Overview

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma and H3 K27M-Mutant High-Grade Glioma

Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This phase 1/2 trial tests the safety, side effects, and best dose and whether selinexor and radiation therapy work in treating patients with newly-diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. A glioma is a type of cancer that occurs in the brain or spine. Glioma is considered high risk (or high-grade) when it is growing and spreading quickly. The term, risk, refers to the chance of the cancer coming back after treatment. DIPG is a subtype of HGG that grows in the pons (a part of the brainstem that controls functions like breathing, swallowing, speaking, and eye movements). Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy to kill tumor cells and shrink tumors. Selinexor and radiation therapy together may be a beneficial treatment for DIPG and H3 K27M-mutant HGG.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)